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In June 2000, vancomycin-intermediate Staphylococcus aureus (VISA) was
isolated from a 27-year-old home health-care patient following a complicated
cholecystectomy. Two VISA strains were identified with identical MICs to all
antimicrobials tested except oxacillin and with closely related pulsed-field gel
electrophoresis types. The patient was treated successfully with antimicro-
bial therapy, biliary drainage, and reconstruction. Standard precautions in
the home health setting appear successful in preventing transmission.
To date, four of the eight cases of infection by Staphylo-
coccus aureus with reduced susceptibility to vancomycin
(vancomycin-intermediate S. aureus [VISA] or glycopeptide-
intermediate  S. aureus  [GISA]) have been reported in the
United States (1-3). We report a fifth case of VISA infection
in the United States, and the first to occur during home
health-care therapy. While all previous VISA strains have
been oxacillin resistant, one of the two VISA strains identi-
fied in this investigation was oxacillin susceptible.
Case Report
The patient, a 27-year-old woman, was well until acute
cholecystitis developed in February 2000. She had under-
gone left nephrectomy and radiation therapy at 4 years of
age for Wilms tumor. There was no evidence of tumor recur-
rence, and she had normal renal function. She worked as a
nurse in several long-term care facilities for 6 years. 
She underwent emergency laparoscopic cholecystectomy
that was complicated by laceration of the common bile duct.
She required open cholecystectomy and placement of a bil-
iary drainage tube (i.e., T-tube). Cefotetan (1,000 mg) had
been given parenterally as perioperative prophylaxis. A T-
tube cholangiogram performed 2 weeks after the procedure
showed no common bile duct obstruction or stricture, and the
T-tube was removed. During the next 2 weeks, fever and
right upper quadrant abdominal pain developed. A computed
tomography (CT) scan of the abdomen demonstrated multi-
ple abscesses in right and left hepatic lobes. Endoscopic ret-
rograde cholangiopancreatography (ERCP) demonstrated
mild narrowing of the common bile duct. A biliary stent was
placed and levofloxacin and metronidazole were adminis-
tered, but the patient's condition did not improve. Aspiration
of one abscess under CT guidance revealed no pathogens. A
bile culture obtained during ERCP stent replacement
identified Candida albicans and oxacillin-resistant S. aureus
(ORSA, vancomycin MIC=2 µg/mL). Intravenous vancomy-
cin, metronidazole, levofloxacin, and fluconazole were
administered, and the patient was transferred from the hos-
pital in Nevada to Los Angeles, where a transhepatic biliary
drainage catheter was placed. In April 2000, she was dis-
charged to home, where she was followed weekly by home
health-care nurses.
Over the next 10 weeks, the patient received ciprofloxa-
cin (500 mg every 12 hours), metronidazole (250 mg every 8
hours), and vancomycin (from 750 mg to 1,100 mg every
day). Serum vancomycin trough levels obtained approxi-
mately once each week were from 2.7 µg/mL to 4.9 µg/mL.
During elective exchange of the transhepatic biliary drain on
June 6, 2000, a culture of bile drainage identified C. albi-
cans, Stenotrophomonas maltophilia, ORSA, and VISA.
After VISA was confirmed, vancomycin therapy was
stopped, and treatment was modified to include linezolid
(600 mg twice a day), trimethoprim-sulfamethoxazole (160
mg and 800 mg twice a day), and doxycycline (100 mg orally
twice a day). After 10 days of therapy, the patient’s condition
improved, and repeat culture of the bile showed no growth of
S. aureus. Six weeks after therapy for VISA was initiated,
the patient underwent reconstruction of the bile duct with a
Roux-en-Y hepaticojejunostomy and removal of intrahepatic
drain. During this hospitalization, therapy for VISA was dis-
continued. Although the VISA infection cleared, the patient
continues to have symptoms of gastroesophageal reflux dis-
ease.
After 24 hours' incubation, primary isolation purity
plates of biliary drainage grew large, yellow, beta-hemolytic
colonies of S. aureus with an oxacillin MIC >16 µg/mL and a
vancomycin MIC of 2 µg/mL by broth microdilution. After 48
hours of incubation, additional small colonies were visible,
and two morphologically distinct strains of S. aureus were
identified on subculture. In the clinical laboratory, vancomy-
cin susceptibility of both strains of S. aureus was determined
by broth microdilution (vancomycin MIC = 8 µg/mL) and was
confirmed by E-test (vancomycin MIC = 6 µg/mL) and
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growth on a brain heart infusion screening plate containing
6 µg of vancomycin. These tests were repeated and con-
firmed on both strains at the Centers for Disease Control
and Prevention. 
The antimicrobial susceptibility profiles of the two
strains were identical for 10 of the 11 antimicrobials tested:
susceptible to gentamicin, tetracycline, quinupristin-dalfo-
pristin, and trimethoprim-sulfamethoxazole; intermediate to
vancomycin and chloramphenicol; and resistant to erythro-
mycin, clindamycin, levofloxacin, ciprofloxacin, and
rifampin. However, strain no. 1 was resistant to oxacillin
(MIC >16 µg/mL) and was  mecA positive by polymerase
chain reaction (4); strain no. 2 was susceptible to oxacillin
(MIC = 0.5 µg/mL) and was mecA negative. 
Before the identification of VISA, the home health-care
agency nurses caring for the patient had routinely used stan-
dard precautions (i.e., washing hands before and after con-
tact with the patient, using gloves for contact with non-
intact skin or mucous membranes, and wearing mask and
eye protection if splashing was anticipated). Because the
patient administered vancomycin and emptied the biliary
drainage reservoir herself, nurses did not wear face shields
or masks before VISA was identified. The nurses’ activities
generally were limited to inspecting and flushing the percu-
taneously inserted central venous catheter. After identifica-
tion of VISA, additional measures were instituted, including
care by a single designated nurse and use of gloves, mask,
and gowns for all patient contact (5).
Before these precautions were instituted, we assessed
possible person-to-person transmission of VISA. Cultures
were obtained on dry cotton swabs from both anterior nares
of the patient, of her household contacts (parents and
spouse), and of  the three nurses who had provided care in
the previous 3 months. Each swab was plated on mannitol
salt agar and incubated for 48 hours at 35°C. S. aureus iso-
lates were initially screened by Staphaurex (Murex Diagnos-
tics Inc., Norcross, GA) and identified by using standard
biochemicals (6). Susceptibility testing was performed by
broth microdilution (7). The patient and one of the three
nurses were nasal carriers of ORSA (vancomycin MIC = 2
µg/mL). Ten days later, the nares of the carrier nurse were
recultured, but no  S. aureus carriage was detected. This
health-care worker had not received topical or systemic anti-
microbial therapy for S. aureus decolonization.
S. aureus strains from the patient and the health-care
worker were compared by pulsed-field gel electrophoresis
(PFGE) using SmaI- and EagI-digested chromosomal DNA
(Figure 1). The patient’s oxacillin-resistant VISA strain was
closely related by SmaI and EagI to the patient’s oxacillin-
susceptible strain of VISA. Although by SmaI the ORSA
strain isolated from the nares of the health-care worker
appeared to be related to the patient’s oxacillin-resistant
strain, by EagI the fragment patterns were different, and
the isolates were classified as unrelated (8). Finally, the
patient’s oxacillin-resistant VISA strain had a similar frag-
ment pattern by SmaI compared with the four previously
reported U.S. VISA strains (2,3,9) (Figure 2). 
Conclusions
This case report has several unique aspects. First, each
of the four previously reported U.S. patients with VISA had
end-stage renal disease; this patient had normal renal
function. Second, one of the patient’s VISA strains did not
contain the mecA gene and was oxacillin susceptible; previ-
ously published cases all contained the  mecA gene. This
patient’s VISA strains likely emerged from the same parent
strain, but one underwent a deletion to become mecA nega-
tive. The reasons for this are unclear and deserve further
study. Third, this infection developed in the home health-
care setting, not in a dialysis or acute-care setting, as did
previous cases. Potential risk factors for VISA, such as pro-
longed exposure to vancomycin, are not limited to dialysis or
acute-care settings, and clinical microbiology laboratorians
and clinicians must be vigilant to recognize these strains in
at-risk patients. This includes retesting  S. aureus isolates
from patients who do not respond to traditional therapy (5).
Finally, this patient was successfully treated by surgery and
pharmacotherapy. It is unclear if this infection would have
Figure 1. Pulsed-field gel electrophoresis profiles of SmaI- and EagI-
Digested DNA. NCTC, National Collection of Type Cultures 8325
control. Lane 1, patient’s oxacillin-resistant vancomycin-intermedi-
ate Staphylococcus aureus (VISA); lane 2, patient’s oxacillin-suscep-
tible VISA; lane 3, patient’s oxacillin-resistant  S. aureus (ORSA,
vancomycin MIC = 2 µg/mL) from anterior nares; lanes 4 and 5, iso-
lates of ORSA (vancomycin MIC = 2 µg/mL) from the health-care
worker’s anterior nares.
Figure 2. Pulsed-field gel electrophoresis profiles of SmaI digested
DNA. NCTC, National Collection of Type Cultures 8325 control.
Lane 1, vancomycin-intermediate Staphylococcus aureus (VISA) iso-
late from Japan, otherwise designated Mu50; lane 2, VISA isolate
from Michigan (7); lane 3, VISA isolate from New Jersey (7); Lane 4,
VISA isolate from New York (1); lane 5, VISA isolate from Illinois
(3); lane 7, patient’s oxacillin-resistant VISA; lane 8, patient’s oxacil-
lin-susceptible VISA; lane 9 patient’s oxacillin-resistant  S. aureus
(ORSA, vancomycin MIC = 2 µg/mL) from anterior nares; lanes 10
and 11, isolates of ORSA (vancomycin MIC=2 µg/mL) from the
health-care worker’s anterior nares.Dispatches
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resolved with either treatment alone. The treatment of VISA
infections reported to date has varied (10). The need for com-
bination therapy is unclear, but previous reports suggest
vancomycin monotherapy is inadequate (9). Until studies
demonstrate efficacy of a particular regimen, clinicians must
rely on the susceptibility profiles of isolates to determine
which antimicrobial therapy is appropriate. Removal of pros-
thetic material or surgical intervention also may play an
integral part in successful treatment.
Similar to previous reports, inadequate dosing of vanco-
mycin for treatment of serious ORSA infection likely contrib-
uted to the emergence of this VISA. The limited
concentration of vancomycin in bile (30% to 50% of serum
levels), poor penetration of this drug into abscesses, and sub-
therapeutic vancomycin dosing may have favored emergence
of VISA. In addition, this patient’s VISA appears to have
emerged from a preexisting S. aureus infection; however, the
isolate that caused this preexisting infection was not avail-
able for study. The original ORSA isolate associated with
this patient’s hepatic abscess may have been acquired dur-
ing her initial hospitalization or previous employment.
Regardless, this VISA appears to be closely related by PFGE
to the other U.S. VISA strains, suggesting certain S. aureus
strains may have a predisposition to express the VISA
phenotype.
As with previous U.S. reports, no evidence suggests that
VISA spread to health-care personnel or contacts. The use of
standard precautions appears to have been sufficient to pre-
vent transmission of this strain from patient to health-care
worker. All health-care agencies should use appropriate
infection control practices to prevent spread of epidemiologi-
cally important organisms from patient to health-care
worker and patient to patient. Having such policies in place,
regardless of the setting, will protect patients and workers
from unnecessary risks. 
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